SinoMab BioScience (HKG:3681) presented the results of preclinical studies of its hC2 at the Society for Investigative Dermatology Annual Meeting 2026 in Chicago on Thursday, according to a same-day Hong Kong bourse filing.
In the preclinical study of the drug in humanized animal models for alopecia areata and vitiligo, hC2 showed favorable tolerability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.